Your browser doesn't support javascript.
loading
Structure-based design of targeted covalent inhibitors.
Lonsdale, Richard; Ward, Richard A.
Afiliação
  • Lonsdale R; Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG, UK. richard.a.ward@astrazeneca.com.
Chem Soc Rev ; 47(11): 3816-3830, 2018 Jun 05.
Article em En | MEDLINE | ID: mdl-29620097
Covalent inhibition is a rapidly growing discipline within drug discovery. Many historical covalent inhibitors were discovered by serendipity, with such a mechanism of action often regarded as undesirable due to potential toxicity issues. Recent progress has seen a major shift in this outlook, as covalent inhibition shows promise for targets where previous efforts to identify non-covalent small molecule inhibitors have failed. Targeted covalent inhibitors (TCIs) can offer drug discovery scientists the ability to increase the potency and/or selectivity of small molecule inhibitors, by attachment of reactive functional groups designed to covalently bind to specific sites in a target. In this tutorial review we introduce the broader concept of covalent inhibition, discuss the potential benefits and challenges of such an approach, and provide an overview of the current status of the field. We also describe some strategies and computational tools to enable successful covalent drug discovery.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Desenho de Fármacos / Bibliotecas de Moléculas Pequenas Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Chem Soc Rev Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Desenho de Fármacos / Bibliotecas de Moléculas Pequenas Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Chem Soc Rev Ano de publicação: 2018 Tipo de documento: Article